OX413

OX413 is a first-in-class decoy oligodeoxynucleotide developed by Onxeo using its proprietary PlatON platform. It is designed to target and hyperactivate poly [ADP-ribose] polymerase 1 (PARP1), acting as a decoy agonist. This hyperactivation leads to PARP trapping, rapid depletion of cellular NAD+ (metabolic exhaustion), and DNA repair abrogation, resulting in selective tumor cell death. Additionally, the accumulation of cytoplasmic chromatin fragments triggers the cGAS/STING pathway, promoting an innate and adaptive immune response. OX413 is being investigated preclinically for the treatment of various cancers, including breast, ovarian, and prostate cancers.